article thumbnail

Upcoming EveryLife Foundation Scientific Workshop on May 21, 2024 will Address Challenges in Developing Therapies for Ultra-Rare Diseases

FDA Law Blog: Drug Discovery

By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C. aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations.

Disease 59
article thumbnail

Perficient to Host Workshop at B2B Connect

Perficient: Drug Development

From June 10-12, B2B Connect will be in San Diego, and Perficient will be hosting a workshop entitled “How to Prioritize Your Direct-to-Consumer Capabilities: What Should I Do Now vs. Next?” If you want to attend the show and our workshop, register at the B2B Connect site.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Workshop addresses oncology dose optimization across full span of development

Agency IQ

BY CHELSEY MCINTYRE, PHARMD , KARI OAKES In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drug development activities.

FDA 59
article thumbnail

Perficient’s Sitecore Personalize Decision Model Workshop

Perficient: Drug Development

In this half day workshop, we’ll work with your team to identify opportunities for optimization and create models that employ the stages, offers and conditions approach to creating a conceptual model for personalization. Interested in learning more? Reach out to me on LinkedIn , Twitter or fill out our contact form.

article thumbnail

Recruiting and retaining patients for successful drug development

Drug Discovery World

The drug development process requires collaboration at all stages, and is particularly important in the rare disease setting, where in addition to pharmaceutical industry stakeholders, patients and patient advocacy groups play a central role.

article thumbnail

Analysis Life Sciences Thank You Workshop addresses oncology dose optimization across full span of development

Agency IQ

Workshop addresses oncology dose optimization across full span of development In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drug development activities.

Science 40
article thumbnail

The role of machine learning in cancer drug development

Drug Discovery World

Throughout the continuum of drug development, from target discovery to patient selection, machine learning approaches are being adopted to reliably mine vast amounts of data and make predictions with higher accuracy Anita Ramanathan discusses how machine learning is currently used across different stages of cancer research. .